GlassScriptPhysician profile
Maria D Mortel
NPI 1447783592
$7,100.46
in general payments reported to CMS, 2019-2025
34 companies · $3,130 in 2025
The $3,130 reported for 2025 was more than what 79% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2021: $132 · 2022: $302 · 2023: $882 · 2024: $2,475 · 2025: $3,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,248 · Travel and Lodging: $239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,247.55 |
| Travel and Lodging | $238.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $842.84 | 2021-2025 | |
| Livanova USA, INC. | $770.59 | 2024-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Neurocrine Biosciences, INC. | $667.79 | 2024-2025 | Ingrezza |
| Pfizer INC. | $477.48 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $418.51 | 2023-2025 | |
| Neurelis, INC. | $414.23 | 2023-2025 | Valtoco |
| Biogen, INC. | $317.68 | 2019-2025 | Vumerity, Tysabri, Plegridy |
| Tg Therapeutics, INC. | $316.55 | 2024-2025 | |
| Neuropace, INC. | $302.29 | 2022 | |
| Ucb, INC. | $290.73 | 2023-2025 | Briviact, Nayzilam, Rystiggo |
| Lundbeck LLC | $285.70 | 2023-2025 | Vyepti, Rexulti |
| Alexion Pharmaceuticals, INC. | $257.33 | 2023-2025 | Ultomiris |
| Sk Life Science, INC. | $207.23 | 2023-2025 | |
| Argenx US, INC. | $194.19 | 2024-2025 | Vyvgart, Vyvgart Hytrulo |
| Eisai INC. | $192.17 | 2023-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $142.28 | 2023-2025 | Kisunla, Amyvid |
| Catalyst Pharmaceuticals, INC. | $131.52 | 2023-2025 | Fycompa |
| Grifols USA, LLC | $123.73 | 2024-2025 | Gamunex-C |
| Teva Pharmaceuticals USA, INC. | $104.29 | 2019 | |
| Ani Pharmaceuticals, INC. | $95.43 | 2025 | Purified Cortrophin Gel |
| Sumitomo Pharma America, INC. | $78.42 | 2023-2024 | Aptiom |
| Genentech USA, INC. | $74.70 | 2023-2025 | Ocrevus Zunovo, Ocrevus, Evrysdi |
| E.R. Squibb & Sons, L.L.C. | $73.13 | 2024 | Zeposia |
| Otsuka America Pharmaceutical, INC. | $65.81 | 2023 | Nuedexta |
| Scilex Pharmaceuticals INC. | $58.63 | 2024-2025 | |
| Medtronic, INC. | $42.61 | 2023 | Activa PC |
| Corium, LLC | $24.62 | 2023 | Adlarity |
| Mallinckrodt Enterprises LLC | $23.22 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $19.98 | 2023 | Evusheld |
| Greenwich Biosciences, INC. | $19.09 | 2019 | |
| Amgen INC. | $18.74 | 2025 | Uplizna |
| Csl Behring | $16.76 | 2025 | Hizentra |
| Impel Pharmaceuticals INC. | $16.35 | 2023 | Trudhesa |
| Janssen Biotech, INC. | $15.84 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Mortel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.